Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1994 Apr 23;308(6936):1068–1073. doi: 10.1136/bmj.308.6936.1068

Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group.

J D Lundgren 1, C Pedersen 1, N Clumeck 1, J M Gatell 1, A M Johnson 1, B Ledergerber 1, S Vella 1, A Phillips 1, J O Nielsen 1
PMCID: PMC2539932  PMID: 7909698

Abstract

OBJECTIVES--To examine the pattern of survival and factors associated with the outcome of disease in patients with AIDS. DESIGN--Inception cohort. Data collected retrospectively from patients' charts. SETTING--52 clinical centres in 17 European countries. SUBJECTS--6578 adults diagnosed with AIDS from 1 January 1979 to 31 December 1989. MAIN OUTCOME MEASURES--Survival after the time of diagnosis. RESULTS--The median survival after diagnosis was 17 months, with an estimated survival at three years of 16% (95% confidence interval 15% to 17%). Patients diagnosed in southern Europe had a shorter survival, particularly immediately after the time of diagnosis, compared with patients diagnosed in central and northern Europe (survival at one year (95% confidence interval) 54% (52% to 56%) 66% (64% to 68%), 65% (63% to 66%), respectively. The three year survival, however, was similar for all regions. The regional differences in survival were less pronounced for patients diagnosed in 1989 compared with earlier years. Improved survival in recent years was observed for patients with a variety of manifestations used to define AIDS but was significant only for patients diagnosed with Pneumocystis carinii pneumonia. The three year survival, however, remains unchanged over time. CONCLUSIONS--Survival of AIDS patients seems to vary within Europe, being shorter in southern than central and northern Europe. The magnitude of these differences, however, has declined gradually over time. Short term survival has improved in recent years, but the long term prognosis has remained equally poor, reflecting the fact that the underlying infection with HIV and many of the complicating diseases remains essentially uncontrolled.

Full text

PDF
1068

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aboulker J. P., Swart A. M. Preliminary analysis of the Concorde trial. Concorde Coordinating Committee. Lancet. 1993 Apr 3;341(8849):889–890. doi: 10.1016/0140-6736(93)93096-j. [DOI] [PubMed] [Google Scholar]
  2. Brenner M., Ognibene F. P., Lack E. E., Simmons J. T., Suffredini A. F., Lane H. C., Fauci A. S., Parrillo J. E., Shelhamer J. H., Masur H. Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis. 1987 Nov;136(5):1199–1206. doi: 10.1164/ajrccm/136.5.1199. [DOI] [PubMed] [Google Scholar]
  3. Buira E., Gatell J. M., Miró J. M., Batalla J., Zamora L., Mallolas J., Aznar E., Soriano E., San Miguel J. G. Influence of treatment with zidovudine (ZDV) on the long-term survival of AIDS patients. J Acquir Immune Defic Syndr. 1992;5(7):737–742. [PubMed] [Google Scholar]
  4. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  5. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  6. Friedland G. H., Saltzman B., Vileno J., Freeman K., Schrager L. K., Klein R. S. Survival differences in patients with AIDS. J Acquir Immune Defic Syndr. 1991;4(2):144–153. [PubMed] [Google Scholar]
  7. Hamilton J. D., Hartigan P. M., Simberkoff M. S., Day P. L., Diamond G. R., Dickinson G. M., Drusano G. L., Egorin M. J., George W. L., Gordin F. M. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992 Feb 13;326(7):437–443. doi: 10.1056/NEJM199202133260703. [DOI] [PubMed] [Google Scholar]
  8. Harris J. E. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA. 1990 Jan 19;263(3):397–401. [PubMed] [Google Scholar]
  9. Lemp G. F., Hirozawa A. M., Cohen J. B., Derish P. A., McKinney K. C., Hernandez S. R. Survival for women and men with AIDS. J Infect Dis. 1992 Jul;166(1):74–79. doi: 10.1093/infdis/166.1.74. [DOI] [PubMed] [Google Scholar]
  10. Lemp G. F., Payne S. F., Neal D., Temelso T., Rutherford G. W. Survival trends for patients with AIDS. JAMA. 1990 Jan 19;263(3):402–406. [PubMed] [Google Scholar]
  11. Moore R. D., Hidalgo J., Sugland B. W., Chaisson R. E. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991 May 16;324(20):1412–1416. doi: 10.1056/NEJM199105163242006. [DOI] [PubMed] [Google Scholar]
  12. Pedersen C., Gerstoft J., Tauris P., Lundgren J. D., Gøtzsche P. C., Buhl M., Salim Y., Schmidt K., Nielsen J. O. Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS. 1990 Nov;4(11):1111–1116. doi: 10.1097/00002030-199011000-00009. [DOI] [PubMed] [Google Scholar]
  13. Peters B. S., Beck E. J., Coleman D. G., Wadsworth M. J., McGuinness O., Harris J. R., Pinching A. J. Changing disease patterns in patients with AIDS in a referral centre in the United Kingdom: the changing face of AIDS. BMJ. 1991 Jan 26;302(6770):203–207. doi: 10.1136/bmj.302.6770.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rothenberg R., Woelfel M., Stoneburner R., Milberg J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987 Nov 19;317(21):1297–1302. doi: 10.1056/NEJM198711193172101. [DOI] [PubMed] [Google Scholar]
  15. Vella S., Giuliano M., Pezzotti P., Agresti M. G., Tomino C., Floridia M., Greco D., Moroni M., Visco G., Milazzo F. Survival of zidovudine-treated patients with AIDS compared with that of contemporary untreated patients. Italian Zidovudine Evaluation Group. JAMA. 1992 Mar 4;267(9):1232–1236. [PubMed] [Google Scholar]
  16. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES